287,815 Shares in Boston Scientific Corporation $BSX Purchased by Corient Private Wealth LP

Corient Private Wealth LP acquired a new position in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, HoldingsChannel reports. The fund acquired 287,815 shares of the medical equipment provider’s stock, valued at approximately $11,241,000.

Other large investors have also modified their holdings of the company. CYBER HORNET ETFs LLC grew its stake in shares of Boston Scientific by 3.4% during the third quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock valued at $391,000 after buying an additional 132 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management lifted its stake in shares of Boston Scientific by 4.7% during the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock worth $294,000 after acquiring an additional 139 shares during the last quarter. Northwestern Mutual Investment Management Company LLC boosted its holdings in Boston Scientific by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider’s stock valued at $4,516,000 after acquiring an additional 140 shares during the period. Kingsview Wealth Management LLC grew its position in Boston Scientific by 2.4% in the 4th quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock valued at $578,000 after acquiring an additional 142 shares during the last quarter. Finally, Uptick Partners LLC grew its position in Boston Scientific by 5.6% in the 4th quarter. Uptick Partners LLC now owns 2,699 shares of the medical equipment provider’s stock valued at $257,000 after acquiring an additional 143 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

BSX has been the topic of a number of recent analyst reports. Mizuho reduced their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. BTIG Research reduced their price target on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 29th. Finally, Needham & Company LLC decreased their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Trading Up 0.3%

BSX opened at $46.82 on Friday. The stock’s fifty day moving average is $46.56 and its two-hundred day moving average is $56.65. The company has a market capitalization of $67.85 billion, a P/E ratio of 18.96, a PEG ratio of 1.02 and a beta of 0.56. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the business earned $0.75 EPS. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig bought 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney bought 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 194,522 shares of company stock worth $9,385,210 over the last three months. 0.34% of the stock is owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.